%0 Journal Article %A Shehu Shagari Awandu %A Alfred Ochieng %A Benson Onyango %A Richard Odongo Magwanga %A Pamella Were %A Angeline Ochung %A Fredrick Okumu %A Marceline Adhiambo Oloo %A Jim Seth Katieno %A Shirley Lidechi %A Fredrick Ogutu %A Dorothy Awuor %A Joy Nyangasi Kirungu %A Francis Orata Omoto %A Justine Midega %A Bonface Oure %A Regina Nyunja %A Eric M O Muok %A Steven Munga %A Benson Estambale %T High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya %D 2022 %R 10.1101/2022.07.27.22278095 %J medRxiv %P 2022.07.27.22278095 %X Background The population’s antibody response is a key factor in comprehending SARS-CoV-2 epidemiology. This is especially important in African settings where COVID-19 impact, and vaccination rates are relatively low. This study aimed at characterizing the Immunoglobulin G (IgG) and Immunoglobulin M (IgM) in both SARS-CoV-2 asymptomatic and symptomatic individuals in Kisumu and Siaya counties in Western Kenya using enzyme linked immunosorbent assays.Results The IgG and IgM overall seroprevalence in 98 symptomatic and asymptomatic individuals in western Kenya between December 2021-March 2022 was 76.5% (95% CI =66.9-84.5) and 31.6% (95% CI =22.6-41.8) respectively. In terms of gender, males had slightly higher IgG positivity 87.8% (36/41) than females 68.4% (39/57). Amidst the ongoing vaccination roll-out during the study period, over half of the study participants (55.1%, 95% CI= 44.7-65.2) had not received any vaccine. About one third, (30.6%, 95% CI= 21.7-40.7) of the study participants had been fully vaccinated, with close to a quarter (14.3% 95% CI=8.04-22.8) partially vaccinated. When considering the vaccination status and seroprevalence, out of the 30 fully vaccinated individuals, IgG seropositivity was 86.7% (95% CI =69.3-96.2) and IgM seropositivity was 40% (95% CI =22.7-59.4). Out of the participants that had not been vaccinated at all, IgG seroprevalence was 70.3% (95% CI 56.4-82.0) with 20.4% (95% CI 10.6-33.5) seropositivity of IgM antibodies. SARs-CoV-2 PCR positivity did not significantly predict IgG (p = 0.457 [95% CI 0.514-4.371]) and IgM (p = 0.858 [95% CI 0.350-2.395]) positivity.Conclusion Our data indicate a high seroprevalence of antibodies to SARS-CoV-2 in western Kenya. This suggests larger fraction of the population were infected with SARS-CoV-2 within the defined period than what PCR testing could cover.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the National Research Foundation-South Africa under the COVID-19 Africa Rapid Grant Fund (Nr: COV19200616532700). SSA is supported by AREF Research Development Fellowship 2022, (AREF-312-AWAN-F-C0907). The funders had no role in study design, data collection and analysis, decision to publish, preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by Jaramogi Oginga Odinga University of Science and Technology ERC/21/5/21-4, and a research license granted from Kenya National Commission of Science and Technology NACOSTI/P/22/17545. Administrative approval was provided by the County governments of Kisumu and Siaya. All participants provided written informed consent or assent before enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files. %U https://www.medrxiv.org/content/medrxiv/early/2022/07/29/2022.07.27.22278095.full.pdf